

Biomodulating Porous Nanomaterials for Oral Drug Delivery

Dr. Tushar Kumeria, PhD

Scientia Senior Lecturer & Head of Porous Materials Lab


School of Materials Science and Engineering

Australian Centre for NanoMedicine

University of New South Wales-Sydney, Australia



3 Laws of Robotics




injure a
through
human
arm.


y orders
i beings
n orders
with the

tect its
long as
oes not
first or


3 Laws of Nanomedicine



Nanomedicine, must achieve its intended function; i.e. diagnosis or therapeutic delivery or both.




Nanomedicine, must only target the diseased/desired organ and not show any off-target effects.



Nanomedicine, must clear out after performing its intended function as non-toxic entities.

3 Laws of Robotics



3 Laws of Nanomedicine

Nanoparticles in the Clinic (mostly for Cancer)

Approved

- Doxil, Gaelyx (1995/1996)
- DaunoXome (1996)
- Myocet (2000)
- Abraxane (2005, 2008)
- Marqibo (2012)
- MEPACT (2009)
- Onivyde (2015)
- CosmoFer, Dexferrum, Ferrlecit, Venofer, Feraheme, Injectafer, Ferinject, Monofer, Dafer, Feridex, Resovist, Ferumoxtran
- Diprivan (1989)
- Ambisome (1997)
- Visudyne (2000/2000)
- Vyxeos (2017)
- Patisiran (2018)

In Clinical Trials (Phase I-III)

Promitil	MRX34	ABI-009
Thermodox	TagomiRs	ABI011
Oncoprex	ND-L02-s0201	AuroLase
Halaven	ARB-001467	NBTXR3
Minoxantrone	CAL02	Cornell Dots
JVRS-100	Nanocort	Magneplate
Lipocurc	RGI-2001	CRLX301
LiplaCis	Sonazoid	AZD2811
MM-302	RadProtect	Bind-014
LIPUSU	Cynviloq	
TKM-080301	Genexol-PM	
PNT2258	Nanoplatin	
BP1001	DACH-Platin	
CDR-MYC	NK105	
Atu027	Decetaxel-PM	
SGT-53	CriPec	
SGT-94		

Mentioned in > 1000 clinical trials in clinicaltrials.gov


Mitragotri et al., *Bioeng. Trans. Med.*, 2016

achieve
on; i.e.
therapeutic

t only
desired
w any


t clear
ng its
on-toxic

Porous Silicon (pSi)




Kokil et al 2023
Raza et al Mater Today Adv 2022
Kumeria et al Sensors 2018 & 2022
Marini et al Adv Funct Mater 2020
Wang et al ACS APMI 2018

Mesoporous Silica (MSN)



Cao et al Biomater Sci 2023
Raza et al Acta Biomater 2022
Altalhi et al Anal Chimica Acta 2021
Raza et al ACS Biomater Sci Eng 2021


Nanoporous Alumina (NAA)



Law et al Sens Actuate B 2022
Kaur et al Anal Chem 2019
Eckstein et al JMC C 2019
Bindra et al Nanotechnology 2018


Porous Nanomaterials in Kumeria Lab

Titania Nanotubes (TiNTs)




Ali et al 2023 (under Revision)
Kumeria et al JMC B 2015

Composite Nanofibers




McKeena et al Biofab 2023
Bakshi et al Adv Funct Mater 2022
Zuidema et al Adv Mater 2018

Porous Silicon Microrods (pSi-MR)



Coming Soon...

Fabrication: Electrochemical Anodization



Fabrication: **P**orous **S**ilicon



Porous Silicon


Drug Delivery

- Oral Delivery/Systemic/Local Delivery
- Protein
- Small Molecules
- Genes

Tissue Engineering


Bioimaging

Sensing




- Cytocompatibility
- High loading capacity
- Tunable release profiles
- Biodegradability


- Tunable pore structure
- Tunable surface chemistry




- Tunable photoluminescence



1. Oral Meropenem Delivery Using pSi-PEG


Name	Structure	Molecular formula	Production	Half-life (hour)	water solubility
Meropenem		C ₁₇ -H ₂₅ -N ₃ -O ₅ -S-H ₂ -O	Synthetic	1.0	5.63mg/mL





Intestinal Efflux

Degradation




Controlled release



pSi-PEG for Efflux Regulation



MER activity retention




Intestinal Efflux ✓


Controlled release ✗

2. Biomodulating Microspheres for oral Meropenem

a Drug loading in MCM





b Pomegranate like Microsphere synthesis



c Efficacy testing

Time dependent and pH responsive release



Mesoporous Silica Nanoparticles (MSN)




**Solids
(S)**







**Dendritics
(D)**



**MCM-41
(M)**



**Rods
(R)**





Structure and Morphology






Large scale production

MCM-48/Eudragit[®] Microspheres

Particle size and surface charge



MCM-48/Eudragit® Microspheres



d

Formulations	Efflux ratio
MER	5.31
MER-Ver	0.09
MER-MCM	1.23
MER-RSPO	0.71
MER-RS100	0.96
MER-S100	0.99


Intestinal Efflux







Controlled release



pSi/Hydrogel Composite







pSi/hydrogel Composite





— Storage Modulus

••••• Loss Modulus


MF release in SNF



pSi/Hydrogel Composite



pSiNPs for Photoacoustic (PA) Bioimaging



pSiNPs for Photoacoustic (PA) Bioimaging




Figure. PA imaging intensity of SiNPs in-vitro

	SiO ₂ NPs	ICG
PA Enhancement	81.2	6.2















Figure. In-vitro and Ex-vivo PA imaging using pSiNPs

Targeting and Degradation of pSiNPs



pSiNPs for Photoacoustic (PA) Bioimaging






Figure. PA imaging intensity of pSiNPs in the GI Tract
N = 4

	SiO ₂ NPs	ICG
PA Enhancement	3.2 ± 0.35	3.7 ± 0.76

Figure. PA imaging using of orally injected ICG, SiO₂, and pSiNPs

Acknowledgements

Institutions











People

- Shrishty Bakshi
- Masood Ali
- Jingwen Wang
- Zanib Chaudhary
- Yuxue Cao
- Zhi Qu
- Dr. Brian Tse
- Dr. Joanna Wang
- Dr. BJ Kim
- Dr. Yousuf Mohammed
- Dr. Kamil Sokolowski
- Dr. Yaowu He
- Dr. Thomas Kyrze
- A/Prof. Amirali Popat
- Dr. Ganesh Kokil
- Dr. Aun Raza
- Dr. Prarthana Rewatkar
- Dr. Harry Parekh
- Dr. Preeti Pandey
- Dr. Helen He
- Astha Sharma
- Prof. Adam Ye
- A/Prof. Abel Santos
- Prof. John Hooper
- Prof. Michael McGuckin
- Prof. Michael Sailor

Funding



Thank You!!



Let's Connect








@TKumeria




Tushar Kumeria

Backup Charts!




3. Biomodulating Spikey Virus-like MSN




In-vitro Permeation Model Development



VSNPs Mediated Permeation




VSNP's Mediated Permeation





VSNP's Mediated Oral Uptake


Caco2





Coculture




B










A



B



C



pSi based Oral Protein Delivery




Figure: SEM and DLS of pSi particles




Figure: SEM images of Eudragit coated pSi formulations








Figure: In-vitro release of IgA2 from pSi-Eudragit formulations

ICG/Functionalized MSN for PA imaging

ICG Loading/Functionalization



Highlighting a research article from the Porcus Biomaterials group at the School of Pharmacy of The University of Queensland.

Efficient photoacoustic imaging using indocyanine-green (ICG) loaded functionalized mesoporous silica nanoparticles

Surface chemistry is an important consideration in the designing of these materials for medical use. This article explores a range of chemical and physical surface chemistries on mesoporous silica for enhanced photoacoustic bioimaging outcome.

As featured in:




See Michael A. McGuffin, Amruti Popat, Tushar Kumeria et al., Biomater. Sci., 2019, 7, 12112





rsc.li/biomaterials-science



Functionalization of MSN



Release and Degradation of ICG




In-vitro PA imaging









The in vitro PA signal enhancement for the ICG loaded **unmodified MSNs**, **PO₃-MSNs**, and **LBMSNs** was close to 2.5-fold, while almost 4-fold PA signal enhancement was observed for **NH₂-MSNs** and **LBLMSN** (at 200 $\mu\text{g mL}^{-1}$ equivalent ICG dose), relative to pure ICG.

PA imaging after bolus injection



The **NH₂- MSNs** displayed an **enhancement of 1.29-fold** compared to the same equivalent dose of pure ICG, whereas the highest PA bioimaging signal enhancement in subcutaneously injected mouse cadavers of **1.43-fold was observed for LBL modified MSNs** in comparison to pure ICG

Self-reporting Ophthalmic Protein Delivery



Self-reporting Ophthalmic Drug Delivery

Luminescent pSi in vivo

